Idiopathic pulmonary fibrosisNews & Research
15 curated articles for Idiopathic pulmonary fibrosis — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- American journal of respiratory and critical care medicine May 5, 2026
Standalone Prognostication of Idiopathic Pulmonary Fibrosis Using Attention-Based Deep Learning.
The prognosis of idiopathic pulmonary fibrosis (IPF) is heterogeneous and challenging to predict. To develop and externally test ORACLE-IPF, a fully automated deep learning model predicting five-year mortality risk from a single baseline chest CT scan. ORACLE-IPF was trained and internally tested us...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Molecular immunology May 2, 2026
Phillyrin attenuates TGF-β1-induced pulmonary fibrosis by modulating the Nrf2/HO-1 pathway and epithelial-mesenchymal transition.
Phillyrin (Phi), a natural lignan glycoside derived from Fructus Forsythiae, has been reported to exhibit anti-inflammatory and antioxidant activities. In this study, we investigated its therapeutic potential in a TGF-β1-induced model of epithelial-mesenchymal transition (EMT) in A549 human al...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Cell May 1, 2026
Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional phenotypes.
Identifying drugs that reverse disease-associated transcriptomic features has been widely explored for drug repurposing, but its potential for de novo drug discovery remains underexplored. Here, we present gene expression profile predictor on chemical structures (GPS), a deep-learning-based drug dis...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Current allergy and asthma reports Apr 29, 2026
Interception of Regulatory RNAs on TGF-β Signaling in the Pathogenesis of Idiopathic Pulmonary Fibrosis: A Systematic Review.
Idiopathic Pulmonary Fibrosis is a type of interstitial lung disease characterized by lung scarring due to excessive extracellular matrix (ECM) deposition. The transforming growth factor-beta (TGF-β) signaling pathway is the master regulator of fibrosis, driving myofibroblast activation and di...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Lung Apr 27, 2026
Circulating Biomarkers for Predicting Disease Progression in Idiopathic Pulmonary Fibrosis: Insights into Precision Medicine.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease with increasing incidence and poor prognosis, with a median survival of approximately 3 years. Although antifibrotic therapies such as nintedanib and pirfenidone offer modest benefits in slowing disease prog...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Cytokine & growth factor reviews Apr 18, 2026
The immunodynamics of pulmonary fibrosis.
Pulmonary fibrosis is the common end-stage pathological outcome of diverse interstitial lung diseases (ILDs), defined by progressive alveolar structural destruction, aberrant extracellular matrix (ECM) deposition, and ultimately fatal respiratory failure. For decades, idiopathic pulmonary fibrosis (...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- European radiology Apr 17, 2026
Progressive pulmonary fibrosis.
A significant number of non-idiopathic pulmonary fibrosis (IPF) cases follow an 'IPF-like' trajectory, known as progressive pulmonary fibrosis (PPF). PPF is associated with increased mortality. One of the criteria for identifying PPF is progression of fibrosis despite conventional treatment on seria...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Trends in pharmacological sciences Apr 3, 2026
Targeting the senescence-autophagy axis for idiopathic pulmonary fibrosis therapy.
Idiopathic pulmonary fibrosis (IPF) is a progressive, age-associated interstitial lung disease with limited therapeutic options. Current antifibrotics modestly slow the decline but fail to halt or reverse fibrosis. Emerging evidence implicates two central hallmarks of aging-cellular senescence and i...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- JAMA Mar 24, 2026
Oral Nalbuphine in Idiopathic Pulmonary Fibrosis-Associated Cough: The CORAL Randomized Clinical Trial.
For patients with idiopathic pulmonary fibrosis (IPF), cough impairs quality of life; effective treatments for IPF-associated cough are needed. To determine if nalbuphine extended release (ER), a κ opioid receptor agonist and μ-opioid receptor antagonist, decreases cough compared with pl...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Drugs Mar 21, 2026
Nerandomilast: First Approval.
Nerandomilast (JASCAYD ® ) is an oral selective phosphodiesterase (PDE) 4B inhibitor developed by Boehringer Ingelheim Pharmaceuticals, Inc. for the treatment of lung fibrosis. It received its first approval on 7 October 2025 in the USA for the treatment of adults with idiopathic pulmonary fibr...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Pulmonary therapy Mar 16, 2026
Emerging Therapies in Pulmonary Fibrosis.
Interstitial lung diseases (ILD) are a heterogenous group of respiratory disorders with varying degrees of inflammation and fibrosis. Idiopathic pulmonary fibrosis (IPF), the commonest and most debilitating type of ILD, is a chronic, progressive disease of the respiratory system characterized by fib...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- The New England journal of medicine Mar 11, 2026
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical observation. In this phase 3, double-blind trial, we randomly assigned patients with IPF to receive in...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- American journal of respiratory and critical care medicine Feb 25, 2026
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.
In the randomized placebo-controlled FIBRONEER-IPF trial in patients with idiopathic pulmonary fibrosis, both nerandomilast 9 mg bid and 18 mg bid met the primary endpoint of reducing decline in forced vital capacity at week 52. Patients continued to receive randomized treatment after ...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Signal transduction and targeted therapy Feb 22, 2026
Parathyroid hormone-related protein is a therapeutic target in idiopathic pulmonary fibrosis.
The crosstalk between immune or alveolar epithelial cells and fibroblasts mediated by paracrine signaling molecules is associated with the pathogenesis of idiopathic pulmonary fibrosis (IPF). However, studies investigating the active involvement of soluble mediators derived from bronchial epithelial...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
- Clinical science (London, England : 1979) Feb 5, 2026
Loss of ATF3 exacerbates pulmonary fibrosis via enhanced neutrophil recruitment and profibrotic macrophage polarization.
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by irreversible scarring, excessive extracellular matrix (ECM) deposition, and progressive loss of pulmonary function. Although innate immune cells, including neutrophils and macrophages, contribute to disea...
Why it matters: Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
More on Idiopathic pulmonary fibrosis
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.